These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22052407)

  • 21. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L; Woodworth G
    Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA
    Cook JA; Julious SA; Sones W; Hampson LV; Hewitt C; Berlin JA; Ashby D; Emsley R; Fergusson DA; Walters SJ; Wilson EC; MacLennan G; Stallard N; Rothwell JC; Bland M; Brown L; Ramsay CR; Cook A; Armstrong D; Altman D; Vale LD
    Health Technol Assess; 2019 Oct; 23(60):1-88. PubMed ID: 31661431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations.
    Schmidli H; Bretz F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):635-43. PubMed ID: 16972715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An alternative phase II/III design for continuous endpoints.
    Huang WS; Liu JP; Hsiao CF
    Pharm Stat; 2011; 10(2):105-14. PubMed ID: 20186724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.
    Fazzari M; Heller G; Scher HI
    Control Clin Trials; 2000 Aug; 21(4):360-8. PubMed ID: 10913810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adapting by calibration the sample size of a phase III trial on the basis of phase II data.
    Martini DD
    Pharm Stat; 2011; 10(2):89-95. PubMed ID: 20140977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
    Brutti P; De Santis F; Gubbiotti S
    Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Closeout of four phase II Vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial.
    Tavel JA; Fosdick L;
    Control Clin Trials; 2001 Feb; 22(1):42-8. PubMed ID: 11165422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian approach to two-stage phase II trial.
    Pepple PA; Choi SC
    J Biopharm Stat; 1997 May; 7(2):271-86. PubMed ID: 9136069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sample size and interim analysis issues for dose selection.
    Lee KL
    Am Heart J; 2000 Apr; 139(4):S161-5. PubMed ID: 10740124
    [No Abstract]   [Full Text] [Related]  

  • 32. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
    Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
    Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bayesian sample size determination for a Phase III clinical trial with diluted treatment effect.
    Zhang YY; Ting N
    J Biopharm Stat; 2018; 28(6):1119-1142. PubMed ID: 29513608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seamlessly expanding a randomized phase II trial to phase III.
    Inoue LY; Thall PF; Berry DA
    Biometrics; 2002 Dec; 58(4):823-31. PubMed ID: 12495136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A decision theoretical modeling for Phase III investments and drug licensing.
    Miller F; Burman CF
    J Biopharm Stat; 2018; 28(4):698-721. PubMed ID: 28920757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting population entering phase III trials: a new stratified adaptive phase II design.
    Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
    Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian models for subgroup analysis in clinical trials.
    Jones HE; Ohlssen DI; Neuenschwander B; Racine A; Branson M
    Clin Trials; 2011 Apr; 8(2):129-43. PubMed ID: 21282293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian adaptive D-optimal design with delayed responses.
    Li J; Fu H
    J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proof-of-principle phase II MRI studies in stroke: sample size estimates from dichotomous and continuous data.
    ; Phan TG; Donnan GA; Davis SM; Byrnes G
    Stroke; 2006 Oct; 37(10):2521-5. PubMed ID: 16931782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adapting the sample size planning of a phase III trial based on phase II data.
    Wang SJ; Hung HM; O'Neill RT
    Pharm Stat; 2006; 5(2):85-97. PubMed ID: 17080765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.